Free Trial
NASDAQ:CHRS

Coherus Oncology (CHRS) Stock Price, News & Analysis

Coherus Oncology logo
$0.87 -0.08 (-8.29%)
As of 02:16 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Coherus Oncology Stock (NASDAQ:CHRS)

Key Stats

Today's Range
$0.82
$0.95
50-Day Range
$0.72
$1.02
52-Week Range
$0.66
$2.43
Volume
1.11 million shs
Average Volume
2.66 million shs
Market Capitalization
$100.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.68
Consensus Rating
Moderate Buy

Company Overview

Coherus Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

CHRS MarketRank™: 

Coherus Oncology scored higher than 76% of companies evaluated by MarketBeat, and ranked 257th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Coherus Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Coherus Oncology has only been the subject of 2 research reports in the past 90 days.

  • Read more about Coherus Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for Coherus Oncology are expected to grow in the coming year, from ($1.05) to ($0.67) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Coherus Oncology is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Coherus Oncology is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Coherus Oncology's valuation and earnings.
  • Percentage of Shares Shorted

    29.97% of the float of Coherus Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Coherus Oncology has a short interest ratio ("days to cover") of 21.2, which indicates bearish sentiment.
  • Change versus previous month

  • Dividend Yield

    Coherus Oncology does not currently pay a dividend.

  • Dividend Growth

    Coherus Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    29.97% of the float of Coherus Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Coherus Oncology has a short interest ratio ("days to cover") of 21.2, which indicates bearish sentiment.
  • Change versus previous month

  • News Sentiment

    Coherus Oncology has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Coherus Oncology this week, compared to 2 articles on an average week.
  • Search Interest

    Only 2 people have searched for CHRS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Coherus Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Coherus Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $73,991.00 in company stock.

  • Percentage Held by Insiders

    Only 8.08% of the stock of Coherus Oncology is held by insiders.

  • Percentage Held by Institutions

    72.82% of the stock of Coherus Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Coherus Oncology's insider trading history.
Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus Oncology and its competitors with MarketBeat's FREE daily newsletter.

CHRS Stock News Headlines

CHRS - Coherus Oncology Inc Key Metrics - Morningstar
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
CHRS Coherus Oncology, Inc.
Coherus Oncology Inc.
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
See More Headlines

CHRS Stock Analysis - Frequently Asked Questions

Coherus Oncology's stock was trading at $1.38 at the start of the year. Since then, CHRS stock has decreased by 36.9% and is now trading at $0.8710.

Coherus Oncology, Inc. (NASDAQ:CHRS) released its quarterly earnings data on Monday, May, 12th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.04. The biotechnology company earned $7.60 million during the quarter, compared to the consensus estimate of $59.79 million.
Read the conference call transcript
.

The following companies are subsidiaries of Coherus Oncology: InteKrin, Coherus Intermediate Corp, InteKrin Russia, and InteKrin Therapeutics Inc..

Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Coherus Oncology investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
5/12/2025
Today
7/15/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CHRS
CIK
1512762
Fax
N/A
Employees
330
Year Founded
2010

Price Target and Rating

High Price Target
$7.00
Low Price Target
$1.05
Potential Upside/Downside
+393.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.13)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$28.51 million
Net Margins
-66.30%
Pretax Margin
24.88%
Return on Equity
N/A
Return on Assets
-26.51%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.22
Quick Ratio
1.20

Sales & Book Value

Annual Sales
$272.25 million
Price / Sales
0.40
Cash Flow
$0.31 per share
Price / Cash Flow
3.02
Book Value
($1.14) per share
Price / Book
-0.83

Miscellaneous

Outstanding Shares
115,933,000
Free Float
106,566,000
Market Cap
$110.10 million
Optionable
Optionable
Beta
0.86

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:CHRS) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners